Establishment of a cholangiocarcinoma risk evaluation model based on mucin expression levels

Figure 7 Establishment of cholangiocarcinoma risk evaluation model based on mucin levels. A: RNA levels of MUC1, MUC13, MUC16, MUC4, MUC5AC and MUC5B in cholangiocarcinoma (CCA) samples from cohort 2; B: Survival curve based on RNA levels of mucins showing the relationship between the risk factor and survival of CCA patients from cohort 2; C-F: Gene set enrichment analysis plots showing the enrichment of differentially expressed genes in high-risk patients in cell proliferation pathway, metastasis pathway, tamoxifen resistance pathway, and cisplatin resistance pathway. The P values and normalized enrichment score are indicated on the plots; G: Survival curve based on protein expression levels of mucins showing the relationship between the risk factor and survival of CCA patients from cohort 2; H-J: Correlation analyses of vascular invasion, regional lymph node metastasis, and tumor node metastasis stage with CCA risk factor; K: Survival curve based on RNA expression levels of mucins showing the relationship between the risk factor and survival of CCA patients from cohort 10.